Drug Interaction Study Of Apixaban With Cyclosporine Or Tacrolimus: Results From A Phase 1, Randomized, Open-Label, Crossover Study In Healthy Volunteers

Authors

Babar Bashir, MD, Thomas Jefferson UniversityFollow
Benjamin D. Tran, PharmD, Thomas Jefferson UniversityFollow
Santhi Mantravadi, MD, Thomas Jefferson UniversityFollow
Douglas F. Stickle, PhD, Thomas Jefferson UniversityFollow
Inna Chervoneva, PhD, Thomas Jefferson UniversityFollow
Walter K. Kraft, MD, Thomas Jefferson UniversityFollow

Files

Description

BACKGROUND

Solid organ transplant recipients commonly require anticoagulation. Apixaban (APX) is principally metabolized by CYP3A4, undergoes direct intestinal excretion, and is a substrate to P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) transporters. We examined the potential drug interaction between cyclosporine (CsA) and tacrolimus (Tac) [combined inhibitors of CYP3A4, P-gp and, BCRP] with APX.

Publication Date

3-2018

Keywords

apixaban, cyclosporine, tacrolimus, transplantation

Disciplines

Medical Pharmacology | Medicine and Health Sciences

Comments

Presented at the American Society for Clinical Pharmacology and Therapeutics Meeting, Orlando, FL March 2018

Recommended Citation

Bashir, MD, Babar; Tran, PharmD, Benjamin D.; Mantravadi, MD, Santhi; Stickle, PhD, Douglas F.; Chervoneva, PhD, Inna; and Kraft, MD, Walter K., "Drug Interaction Study Of Apixaban With Cyclosporine Or Tacrolimus: Results From A Phase 1, Randomized, Open-Label, Crossover Study In Healthy Volunteers" (2018). Department of Pharmacology and Experimental Therapeutics Posters. 5.
https://jdc.jefferson.edu/petposters/5